Dakota Wealth Management Sells 67 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Dakota Wealth Management cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,327 shares of the biopharmaceutical company’s stock after selling 67 shares during the quarter. Dakota Wealth Management’s holdings in Regeneron Pharmaceuticals were worth $1,395,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. SteelPeak Wealth LLC lifted its stake in Regeneron Pharmaceuticals by 173.0% in the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock worth $1,148,000 after purchasing an additional 692 shares during the last quarter. Atria Investments Inc lifted its stake in shares of Regeneron Pharmaceuticals by 12.2% in the 1st quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock valued at $8,317,000 after acquiring an additional 941 shares during the last quarter. Tri Locum Partners LP lifted its stake in shares of Regeneron Pharmaceuticals by 104.5% in the 2nd quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock valued at $18,410,000 after acquiring an additional 8,949 shares during the last quarter. Nordea Investment Management AB boosted its holdings in Regeneron Pharmaceuticals by 23.2% during the 1st quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock valued at $28,218,000 after acquiring an additional 5,495 shares during the period. Finally, Tidal Investments LLC grew its position in Regeneron Pharmaceuticals by 16.8% during the 1st quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock worth $4,774,000 after acquiring an additional 711 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now directly owns 4,204 shares of the company’s stock, valued at $4,498,280. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the transaction, the vice president now directly owns 4,204 shares of the company’s stock, valued at $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.48% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on REGN shares. BMO Capital Markets reiterated an “outperform” rating and issued a $1,300.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Leerink Partners reiterated a “market perform” rating and set a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Wells Fargo & Company dropped their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, October 22nd. Leerink Partnrs cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Finally, Barclays lowered their price objective on shares of Regeneron Pharmaceuticals from $1,220.00 to $1,080.00 and set an “overweight” rating for the company in a research note on Wednesday. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,101.00.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $933.02 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $769.19 and a 12 month high of $1,211.20. The firm has a market capitalization of $102.86 billion, a P/E ratio of 24.71, a P/E/G ratio of 3.29 and a beta of 0.12. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The business has a fifty day simple moving average of $1,088.44 and a two-hundred day simple moving average of $1,039.86.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. During the same period last year, the business earned $8.79 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.66 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.